Cargando…
Bevacizumab in the treatment of ovarian cancer
Despite advances in surgical cytoreduction and cytotoxic chemotherapy, ovarian cancer continues to be the leading cause of death in women with gynecologic malignancy. Our understanding of the treatment of ovarian cancer was revolutionized with the discovery of platinum- and taxane-based adjuvant che...
Autores principales: | Eskander, Ramez N, Randall, Leslie M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044789/ https://www.ncbi.nlm.nih.gov/pubmed/21383911 http://dx.doi.org/10.2147/BTT.S13071 |
Ejemplares similares
-
Emerging treatment options for management of malignant ascites in patients with ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2012) -
Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2013) -
EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers
por: Alldredge, Jill K., et al.
Publicado: (2017) -
Critical appraisal of bevacizumab in the treatment of ovarian cancer
por: Yoshida, Hiroyuki, et al.
Publicado: (2015) -
Immunotherapy in endometrial cancer - an evolving therapeutic paradigm
por: Longoria, Teresa C., et al.
Publicado: (2015)